AstraZeneca shares drop 7% on Bristol Myers megadeal talk
CNBC reported a 7% AstraZeneca share drop after talks of a $400 billion merger with Bristol Myers Squibb; Sort Brick has no price record for the day.
What's happening
The Guardian, Reuters, CNBC, Yahoo Finance and 36kr reported that AstraZeneca was in talks with Bristol Myers Squibb on a merger valued at about $400 billion, with some reports citing the Financial Times. CNBC’s headline said AstraZeneca shares dropped 7% after the report. The on-subject items were published 8 to 17 hours before the story.
The numbers
The 7% drop is taken from CNBC’s headline, since Sort Brick recorded no AstraZeneca price for the story day. Chatter stats were velocity 8.0, breadth 2 and 14 recent mentions.
Our read
This is the rare case where chatter and price move together in the same news cycle — the market didn't wait for confirmation, it priced in dilution and execution risk on a deal this size immediately. Verdict: real. Watch for whether AstraZeneca confirms or denies talks, and whether the 7% drop holds or reverses.
Context
Sort Brick has no earlier or later stories on AstraZeneca or this merger talk in its data, so no earlier verdict can be compared. No daily price history is given, so the story-day price cannot be placed in a 30- or 90-day range, and no price path after the story is shown. The only price figure is the 7% drop in CNBC’s headline. The chatter record is 14 recent mentions, breadth 2 and velocity 8.0. The verdict of real rests on that headline and on coverage from several outlets, but the data does not show whether the talks were confirmed or denied.
Sources we checked
- AstraZeneca holds talks with Bristol Myers Squibb over $400bn merger — theguardian.com
- AstraZeneca shares drop 7% after report on $400 billion merger talks with Bristol Myers Squibb — cnbc.com
- AstraZeneca considering a $400 billion merger with Bristol Myers Squibb — 36kr.com
- AstraZeneca in talks with Bristol Myers Squibb on $400 billion megadeal, FT reports — CNBC
- AstraZeneca held talks with Bristol Myers Squibb on $400 billion megadeal, source says — Reuters
- AstraZeneca and Bristol-Myers Squibb in talks over potential merger - Report — Yahoo Finance
- AstraZeneca holds talks with Bristol Myers Squibb on $400 billion megadeal, FT reports — Reuters
- AstraZeneca Said to Discuss Merger with Bristol Myers Squibb — 36kr.com
See today's live board
This story is frozen as published on August 3, 2026. The live board shows what is moving right now, scored against real money.
Open this story live → See today's live boardMore Stocks stories
- Atkore jumps 28% on Prysmian's $2.5bn takeover bid August 3, 2026
- SEC pauses Nasdaq bitcoin options after CME objection August 3, 2026
- Alibaba ships 2.4-trillion-parameter Qwen3.8-Max model August 3, 2026
- AstraZeneca in $400bn talks to buy Bristol Myers Squibb August 3, 2026
- DJT Slides as Trump Media's Bitcoin Buffer Shrinks August 3, 2026
- Microsoft's Azure Milestone Adds $450 Billion in a Day August 3, 2026
Research, not financial advice. Sort Brick reports what its data showed at the time of publication. It is not a recommendation to buy or sell anything — you decide.